PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.10%
Revenue growth under 50% of CSIQ's 38.96%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
15.31%
Gross profit growth under 50% of CSIQ's 38.54%. Michael Burry would be concerned about a severe competitive disadvantage.
44.28%
EBIT growth 50-75% of CSIQ's 81.12%. Martin Whitman would suspect suboptimal resource allocation.
23.57%
Operating income growth under 50% of CSIQ's 53.93%. Michael Burry would be concerned about deeper cost or sales issues.
42.88%
Net income growth under 50% of CSIQ's 103.04%. Michael Burry would suspect the firm is falling well behind a key competitor.
34.48%
EPS growth under 50% of CSIQ's 101.54%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
34.48%
Diluted EPS growth under 50% of CSIQ's 102.56%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.29%
Share reduction more than 1.5x CSIQ's 0.61%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.29%
Diluted share count expanding well above CSIQ's 0.37%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
87.22%
OCF growth under 50% of CSIQ's 513.84%. Michael Burry might suspect questionable revenue recognition or rising costs.
77.66%
FCF growth 75-90% of CSIQ's 89.91%. Bill Ackman might push for improved capital allocation or operational changes to match the competitor.
-44.47%
Negative 10Y revenue/share CAGR while CSIQ stands at 316.08%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-16.93%
Negative 5Y CAGR while CSIQ stands at 229.29%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
27.52%
3Y revenue/share CAGR under 50% of CSIQ's 210.73%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
81.97%
OCF/share CAGR of 81.97% while CSIQ is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
88.61%
OCF/share CAGR of 88.61% while CSIQ is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-181.21%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-210.21%
Negative 10Y net income/share CAGR while CSIQ is at 1002.91%. Joel Greenblatt sees a major red flag in long-term profit erosion.
94.38%
Below 50% of CSIQ's 889.36%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-256.41%
Negative 3Y CAGR while CSIQ is 654.52%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-65.63%
Negative equity/share CAGR over 10 years while CSIQ stands at 490.31%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
1001.41%
5Y equity/share CAGR above 1.5x CSIQ's 108.20%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
1362.76%
3Y equity/share CAGR above 1.5x CSIQ's 48.44%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.28%
AR growth is negative/stable vs. CSIQ's 21.98%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
11.05%
We show growth while CSIQ is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
5.45%
Asset growth well under 50% of CSIQ's 13.93%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-5.37%
We have a declining book value while CSIQ shows 40.52%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
22.31%
Debt growth far above CSIQ's 8.25%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-10.20%
Our R&D shrinks while CSIQ invests at 33.69%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-8.99%
We cut SG&A while CSIQ invests at 36.07%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.